Match!

Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study

Published on May 6, 2019in Journal of Crohns & Colitis7.83
· DOI :10.1093/ecco-jcc/jjz088
Bénédicte Caron (UDS: University of Strasbourg), Laurent Peyrin-Biroulet57
Estimated H-index: 57
(University of Lorraine)
+ 22 AuthorsGetaid
  • References (23)
  • Citations (1)
References23
Newest
#1Tom H. Karlsen (University of Oslo)H-Index: 44
#2Trine Folseraas (Oslo University Hospital)H-Index: 14
Last.Mette Vesterhus (Oslo University Hospital)H-Index: 14
view all 4 authors...
#1W. A. Bye (John Radcliffe Hospital)H-Index: 1
#2Vipul Jairath (UWO: University of Western Ontario)H-Index: 12
Last.Simon Travis (John Radcliffe Hospital)H-Index: 63
view all 3 authors...
#1Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 126
#2Bruce E. Sands (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 68
Last.I. Fox (Takeda Pharmaceutical Company)H-Index: 13
view all 14 authors...
#1Gideon M. Hirschfield (NIHR: National Institute for Health Research)H-Index: 46
#2Tom H. Karlsen (University of Bergen)H-Index: 44
Last.David H. Adams (NIHR: National Institute for Health Research)H-Index: 100
view all 4 authors...
View next paperP347 Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAID